Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, Kavanaugh WM, Vasiljeva O, Belvin M, Howng B, Irving B, Tipton K, West J, Mei L, Korman AJ, Sega E, Olivera I, Cirella A, Ochoa MC, Rodriguez ME, Melero A, Sanmamed MF, Engelhardt JJ, Melero I. Etxeberria I, et al. Among authors: irving b. Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):e2025930118. doi: 10.1073/pnas.2025930118. Proc Natl Acad Sci U S A. 2021. PMID: 34172583 Free PMC article.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Among authors: irving b. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485 Free PMC article.
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, Yu W, Koditek D, Winter MB, Moore SJ, Mei L, Diep L, Huang Y, Liu S, Vasiljeva O, West J, Richardson J, Irving B, Belvin M, Kavanaugh WM. Boustany LM, et al. Among authors: irving b. Cancer Res. 2022 Nov 15;82(22):4288-4298. doi: 10.1158/0008-5472.CAN-21-2483. Cancer Res. 2022. PMID: 36112781 Free PMC article.
Role of PD-1 during effector CD8 T cell differentiation.
Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R. Ahn E, et al. Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13. Proc Natl Acad Sci U S A. 2018. PMID: 29654146 Free PMC article.
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A. Junttila TT, et al. Among authors: irving b. Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228655
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. Adusumilli PS, et al. J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28649381 Free PMC article. Review.
167 results